Pyrazinoic Acid Conjugates for Tuberculosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tuberculosis using pyrazinamide (PZA) face challenges due to its side effects, such as hepatitis, hypertension, and gastrointestinal discomfort, and the instability of its prodrug derivatives, which limits its effectiveness and safety.
Innovation Solution
Development of PZA conjugates and hybrids with specific structures, including alkyl, alkenyl, or aryl groups and carboxylic acid or nicotinic acid derivatives, which are designed to improve the stability and absorption of pyrazinoic acid, allowing for effective treatment of tuberculosis with reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pyrazinamide (PZA) is used to treat tuberculosis, then antibacterial activity is achieved, but side effects such as hepatitis, hypertension, and gastrointestinal discomfort occur
Solution Approach 1:
The patent introduces prodrug derivatives as intermediary compounds that convert to pyrazinoic acid in the target organism. These prodrugs serve as carriers that deliver the active metabolite selectively to Mycobacterium tuberculosis, reducing systemic exposure and associated side effects while maintaining antibacterial efficacy. Examples include ester prodrugs that require enzymatic conversion to release the active pyrazinoic acid.
Solution Approach 2:
The patent modifies the chemical parameters of pyrazinamide by creating derivatives with different physical and chemical properties. By changing parameters such as lipophilicity, molecular weight, and metabolic stability through structural modification, the patent achieves improved pharmacokinetic profiles that reduce adverse effects while maintaining therapeutic activity against TB.
2Object-affected harmful factors
If pyrazinamide prodrug derivatives are developed to reduce side effects, then safety is improved, but stability of the prodrug derivatives deteriorates
Solution Approach 1:
The patent systematically evaluates and optimizes chemical parameters of prodrug candidates to achieve the right balance between stability and bioavailability. By adjusting parameters such as ester chain length, substituent groups, and molecular structure, the patent creates prodrugs that remain stable during storage and transport but convert efficiently in the target organism.
Solution Approach 2:
The patent creates composite molecular structures combining pyrazinamide core with various functional groups and molecular moieties. These composite prodrug structures integrate the antibacterial activity of pyrazinoic acid with the stability and pharmacokinetic properties of the conjugating groups, achieving both safety and stability requirements.
3Reliability
If pyrazinoic acid is used directly, then antibacterial activity is achieved, but absorption by gastrointestinal tract is poor due to low lipophilicity
Solution Approach 1:
The patent uses prodrug derivatives as intermediary compounds that facilitate absorption. These prodrugs are designed with lipophilic characteristics that enable them to cross the gastrointestinal tract membrane, and they subsequently convert to pyrazinoic acid in the target tissue, solving the absorption problem of the active metabolite itself.
Solution Approach 2:
The patent modifies the lipophilicity parameter of pyrazinoic acid by conjugating it with lipophilic groups and molecular structures. This changes the physical property of the compound to enhance membrane permeability and absorption in the gastrointestinal tract, while the active metabolite remains capable of exerting antibacterial activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PZA conjugates and hybrids demonstrate enhanced antibacterial activity against Mycobacterium species, including Mycobacterium marinum and Mycobacterium fortuitum, with improved stability and absorption, potentially reducing side effects and increasing treatment efficacy.
Implementation Method 1
PZA is perceived to inhibit vital ribosomal proteins after being converted into its active constituent, pyrazinoic acid (POA), by the tuberculosis enzyme, pyrazinamidase (PZAase)
Implementation Method 2
It may lower the pH of the area surrounding M. tuberculosis to such an extent that the organism is unable to grow
Data Source
AI summary
Pyrazinamide (PZA) conjugates and hybrids are provided herein. The PZA conjugates are useful for treating bacterial infections. In one embodiment, the PZA conjugates are useful for treating tuberculosis.